BOSTON—Steven P. Coen, the Chief Accounting Officer at Ginkgo Bioworks Holdings, Inc. (NYSE:DNA), recently sold shares of the company's Class A Common Stock valued at approximately $4,933. The ...

Boston, MA – Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) recently reported a stock transaction by its Chief Financial Officer, Mark E. Dmytruk, according to a recent SEC filing. The transaction comes as ...

Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

Coherent reported quarterly earnings of 95 cents per share which beat the analyst consensus estimate of 69 cents per share. The company reported quarterly sales of $1.44 billion which beat the analyst ...

Ginkgo Bioworks Holdings, Inc.’s DNA share price has dipped by 16.38%, which has investors questioning if this is right time to buy.

Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts. Find out why I maintain a ...

Ginkgo Bioworks (DNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

That’s because it’s gradually dawning on investors that they no longer can count on lower interest rates and inflation to support higher stock and bond prices. They are realizing that ...